This story described the results of a recent study which found that more intense treatment of acute kidney injury resulted in neither improved nor worsened outcomes. The story provided factual information about the study. It also indicated that there could be cost savings to the health care system if additional treatment which failed to provide benefit was avoided.
However, the story failed to tell readers:
There was not explicit information in this story about costs to the individual undergoing care, though one could surmise that less intense treatment would cost less. The story included estimates of the impact from the results of the study on costs to the health care system.
The story did mention that the two approaches to treating acute kidney injury did not have different outcomes and specifically mentioned death rates, recovery of kidney function and rates of other organ failure. The story also mentioned a death rate in one health care system of 50-80% from acute kidney injury.
The story explained that "There was no difference in death rates in both groups, and both also had similar rates of recovering kidney function and other organ failure."
But the story did not provide a clear picture of the view from patient perspective about how the two treatment approaches differed.
The story explained explicitly that the results discussed came from a large, multicenter, randomized clinical trial. It mentioned where the results of the study discussed were going to be published.
The story would have been more helpful if it had included a few words indicating the strength of the study design.
The story did not engage in overt disease mongering.
There is no evidence that the newspaper interviewed anyone for this story. The perspectives of the study’s lead author and of the editorial writer both appear to be gleaned directly from the New England Journal of Medicine.
The story would have been improved by including comments from interviews with clinicians about what this information means to people who may need to deal with acute kidney injury in the future.
The story sketched out two modes of treatment for acute kidney injury which did not appear to differ from one another in terms of outcomes. It was not clear from the story whether one represented standard care or not. In addition, there was no discussion of whether there are choices to be made by patients who experience acute kidney injury.
It is not clear from this story whether both intensities of treatment are in general use and if not, which represented usual care. In addition, treatment of kidney injury is complicated and it was not clear from this story how an individual would weigh in about treatment preference.
It was not clear from the story whether both approaches to treating acute kidney injury were currently in use; are there regional differences; or whether there were other factors affecting the type of treatment a patient with acute kidney injury would receive.
We can’t be sure if the story relied solely or largely on a news release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like